None listed
Conditions
Interventions
Therapy with NeoRecormon® once a week in anemic patients with low-grade non-Hodgkins lymphoma, chronic lymphocytic leukemia or multiple myeloma.
Sponsors
PRODUCTOS ROCHE Q.F.S.A.,
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult patients with a histologically confirmed diagnosis of low-grade non-Hodgkin´s lymphoma, chronic lymphocytic leukemia or multiple myeloma. 2. Hemoglobin of 6 months. 7. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. Transfusion of red blood cells during the 2 months prior to the first planned dose of the study medication. 2. Hypertension refractory to treatment. 3. Major acute or chronic bleeding requiring therapy within 3 months prior to the start of study treatment (patient with anemia caused by gastrointestinal bleeding). 4. Antineoplastic therapy in the week prior to the screening visit except use of corticosteroids and / or low dose of chlorambucil (Leukeran®). 5. Patients scheduled to receive bone marrow transplantation during the period of the treatment study. 6. Functional iron deficiency, for example transferrin saturation 105 fL. 9. Folic acid deficiency, example MCV of erythrocyte> 105 μL. 10. Haemolysis: Haptoglobin <30 mg / dl (3.54 pmol / L) or other verifiable positive test for hemolysis. 11. Epilepsy. 12. Pregnancy or lactation period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated | — |
Countries
Peru
Outcome results
None listed